Summary

Ambulatory Blood Pressure Monitoring Devices Market Growth & Trends

The global ambulatory blood pressure monitoring devices market size is expected to reach USD 1.87 billion by 2030, expanding at a CAGR of 8.45% from 2024 to 2030, according to a new study by Grand View Research, Inc. The driving factors accelerating the growth of this market include the increasing geriatric population, the prevalence of chronic disorders such as hypertension, and technological advancement worldwide. According to the statistics published by WHO, around 1.13 billion people are likely to suffer from hypertension and causing 7.6 million deaths annually.

In addition, high blood pressure is a major risk factor for hemorrhagic stroke and coronary heart disease in this decade. For instance, as per WHO, an estimated 1.28 billion adults who are aged between 30-79 years globally suffer from hypertension, whereas 42.0% of the adults having hypertension are not aware that they have the condition. Hypertension, besides being the most prevalent, is also the leading cause of cardiovascular disease, premature mortality, and disability. It poses a significant economic burden.

Aging population is another driving factor accelerating the growth of the market. As per the recent WHO statistical data published in October 2022, 1 in 6 people would be over 60 years of age worldwide by 2030 and this number would be doubled by 2050. Moreover, cardiovascular diseases are highly prevalent in the older age population.

Also, technological advancement in ambulatory blood pressure monitoring (ABPM) devices is likely to boost the market over the forecast period. Manufacturing of digital technology-based and mobile blood pressure devices fueling the demand of consumers. Key players in the market consistently focus on the development of cost-friendly, innovative, and easy-to-use devices is likely to strengthen the demand of the market.

Ambulatory Blood Pressure Monitoring Devices Market Report Highlights

• Based on the product, instrument & accessories dominated the market and accounted for 67.5 % of global revenue in 2023 owing to constant technological advancements such as improvements in wearable technology, apps, & mobiles, their accessibility, and simplicity in usage

• Based on the type, the blood pressure cuff segment dominated the market with a revenue share of 56.3% in 2023 due to higher accuracy, reliability of data collection, and flexibility in usage provided by blood cuff

• Based on the end-use, ambulatory surgical centers & clinics accounted for largest share of 63.7 % of the ABPM devices market in 2023 owing to increasing number of ambulatory surgeries due to short duration of stay and cost savings

• Based on Based on the region, North America dominated the global ABPM devices market with a revenue share of 39.5 in 2023 owing to increase in product launches by key companies, rising overall healthcare expenditure, and an increase in several regulatory approvals

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Type
1.2.3. End-use
1.2.4. Sales Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Typeoutlook
2.2.3. End-use outlook
2.2.4. Sales channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Ambulatory Blood Pressure Monitoring Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of androgenic alopecia
3.2.1.2. Technological advancements in androgenic alopecia
3.2.2. Market restraint analysis
3.2.2.1. Lack of reimbursement policies for androgenic alopecia
3.2.3. Market opportunity analysis
3.2.3.1. Increasing prevalence of chronic diseases
3.3. Ambulatory Blood Pressure Monitoring Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Ambulatory Blood Pressure Monitoring Devices Market: Prevalence Data, By Region
3.4.1. North America
3.4.1.1. U.S.
3.4.1.2. Canada
3.4.2. Europe
3.4.2.1. UK
3.4.2.2. Germany
3.4.2.3. France
3.4.2.4. Italy
3.4.2.5. Spain
3.4.2.6. Denmark
3.4.2.7. Sweden
3.4.2.8. Norway
3.4.3. Asia Pacific
3.4.3.1. Japan
3.4.3.2. China
3.4.3.3. India
3.4.3.4. South Korea
3.4.3.5. Australia
3.4.3.6. Thailand
3.4.4. Latin America
3.4.4.1. Brazil
3.4.4.2. Mexico
3.4.4.3. Argentina
3.4.5. Middle East and Africa (MEA)
3.4.5.1. South Africa
3.4.5.2. Saudi Arabia
3.4.5.3. UAE
3.4.5.4. Kuwait
Chapter 4. Ambulatory Blood Pressure Monitoring Devices Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Ambulatory Blood Pressure Monitoring Devices Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Ambulatory Blood Pressure Monitors
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Instrument & Accessories
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Ambulatory Blood Pressure Monitoring Devices Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Ambulatory Blood Pressure Monitoring Devices Market by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Blood Pressure Cuffs
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Others Type
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Ambulatory Blood Pressure Monitoring Devices Market: End-use Estimates & Trend Analysis
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Ambulatory Blood Pressure Monitoring Devices Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Homecare
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Ambulatory Blood Pressure Monitoring Devices Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Omron Healthcare Welch Allyn, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. A&D Medical Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Microlife Corporation
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Daray Medical
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Withings
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Briggs Healthcare
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. GE Healthcare
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Rossmax International Ltd.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. GF Health Products Inc
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Spacelabs Healthcare Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Philips Healthcare
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. Biobeat
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Spacelabs Healthcare Inc
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Product benchmarking
8.3.16.4. Strategic initiatives
8.3.17. Bosch & Sohn GmbH & Co. KG
8.3.17.1. Company overview
8.3.17.2. Financial performance
8.3.17.3. Product benchmarking
8.3.17.4. Strategic initiatives
8.3.18. GE Company,
8.3.18.1. Company overview
8.3.18.2. Financial performance
8.3.18.3. Product benchmarking
8.3.18.4. Strategic initiatives
8.3.19. Schiller AG
8.3.19.1. Company overview
8.3.19.2. Financial performance
8.3.19.3. Product benchmarking
8.3.19.4. Strategic initiatives
8.3.20. DAIFUKU CO. LTD
8.3.20.1. Company overview
8.3.20.2. Financial performance
8.3.20.3. Product benchmarking
8.3.20.4. Strategic initiative